<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AFB6A546-016B-4320-B731-A2461A684571"><gtr:id>AFB6A546-016B-4320-B731-A2461A684571</gtr:id><gtr:name>University of Wollongong</gtr:name><gtr:address><gtr:line4>Wollongong</gtr:line4><gtr:line5>NSW 2522</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AFB6A546-016B-4320-B731-A2461A684571"><gtr:id>AFB6A546-016B-4320-B731-A2461A684571</gtr:id><gtr:name>University of Wollongong</gtr:name><gtr:address><gtr:line4>Wollongong</gtr:line4><gtr:line5>NSW 2522</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DB09169F-C399-47A3-8541-9D5CF30B019B"><gtr:id>DB09169F-C399-47A3-8541-9D5CF30B019B</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:otherNames>Reiko</gtr:otherNames><gtr:surname>Kumita</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/88808AB5-21F0-4690-9E5E-AD1329DE1BBC"><gtr:id>88808AB5-21F0-4690-9E5E-AD1329DE1BBC</gtr:id><gtr:firstName>Carol</gtr:firstName><gtr:otherNames>V</gtr:otherNames><gtr:surname>Robinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D099FFE8-DF94-462F-8B16-B943AA467BFC"><gtr:id>D099FFE8-DF94-462F-8B16-B943AA467BFC</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Dobson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FE019927%2F1"><gtr:id>3B89A9F4-ABCA-4870-8617-D6A514C2567E</gtr:id><gtr:title>Elucidating the Mechanism of Amyloid Formation by Human Lysozyme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E019927/1</gtr:grantReference><gtr:abstractText>Our bodies contain some 100,000 proteins that enable or regulate essentially every chemical or biochemical process on which our lives depend. Under normal circumstances these proteins remain in their soluble functional states, but under other circumstances, for example as a result of mutations or even the impairment of regulating processes, they can form large insoluble aggregates that are non-functional and even toxic. This process is of great importance because it is the underlying origin of a range of debilitating human disorders, including neurodegenerative conditions such as Alzheimer's disease, the transmissible spongiform encephalopathies (such as CJD, the human analogue of 'mad cow disease'), type 2 (late onset) diabetes and systemic pathologies in which large quantities, sometimes kilograms, of protein are deposited in vital organs such as the kidney, heart and liver. In each of these diseases, a single protein undergoes a structural transition, often resulting in the formation of thread-like aggregates known as amyloid fibrils. Many of these diseases are linked to the ageing process, and as a large fraction of the world's population lives to ages unprecedented in human history, these diseases are emerging as among the most feared and debilitating in the modern world. In recent years, much research has focused on understanding what causes proteins to misfold and form amyloid structures, and on the specific mechanism by which such transitions occur. Nevertheless, as a result of structural heterogeneity, low populations and a transient nature, obtaining detailed information about this process has presented a formidable challenge. The primary objective of this study is to elucidate structural information of the different species that are populated along the aggregation pathway of human lysozyme. As well as being associated with a systemic amyloid disorder, lysozyme is one of the most highly studied of all proteins providing a unique opportunity to probe the difference between normal and aberrant behaviour at atomic resolution. By studying species populated under fibril forming conditions, we will be able to begin to understand not only the structures of intermediate species, but also the dynamics of the conversion between the different states involved in fibril formation. These studies should generate a sufficiently profound understanding of the distinctive differences between species involved in normal and aberrant folding behaviour to contribute significantly to the identification of novel strategies through which rational therapeutic intervention could lead to prevention or treatment, not just of this specific disease, but also perhaps the entire family of protein misfolding disorders.</gtr:abstractText><gtr:technicalSummary>The overall objective of this study is to understand how soluble proteins convert into amyloid fibrils. We intend to achieve this aim by determining the structural features of the transient species which are populated throughout fibril formation, and to gain an understanding of the dynamic interactions between these states in unprecedented detail. In this study, we will generate mutational lysozyme variants to vary the population of the transient species. We will also employ naturally occurring (i.e. chaperones) and engineered biomolecules (i.e. antibody fragments) that interact with species along the aggregation pathway to try and trap these species for analysis. Once methods are established to populate these species, we will study the system under fibril forming conditions and in a time dependent manner, using an array of established biophysical techniques, in particular exploiting recent advances in NMR spectroscopy and nanospray mass spectrometry. We have established NMR relaxation techniques that probe the structures and stabilities of transient protein folding intermediates with populations as low as 1% that are in dynamic equilibrium with other states. We have also developed mass spectrometry methods for detecting protein assemblies exceeding 1 MDa in size, along with procedures that enable us to define both the stoichiometric and topological arrangement within such complexes. We shall use both these approaches to probe the nature and populations of oligomeric intermediates in lysozyme aggregation, along with similar studies of the species formed on interaction with other macromolecules. These complementary spectroscopic methods, along with our established ability to use theoretical and computational techniques for interpreting these types of data gives us an unrivalled opportunity to define the structural and dynamic character of fibril formation by a globular protein and to explore the manner in which such a process can be controlled or inhibited.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>559041</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Wollongong</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Collaboration with Prof. Mark Wilson, University of Wollongong, Australia</gtr:description><gtr:id>80F98A04-B16A-4353-BED5-B3423F167390</gtr:id><gtr:piContribution>We have also established a strong collaboration with the research group of Prof. Mark Wilson at the University of Wollongong, NSW, Australia. Through this collaboration, we have demonstrated that extracellular chaperones (clusterin, haptoglobin and alpha2-macroglobulin) can inhibit in vitro lysozyme fibril formation when present at highly substoichiometric concentrations and the mechanism by which these chaperones act is through interactions with soluble oligomeric species present during aggregation (Yerbury et al., FASEB J., 2007; Kumita et al, JMB, 2007, Yerbury et al., JBC, 2009).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2002-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>1) We engineered a novel mutation into lysozyme (I59T) to provide an additional tool for comparison with the wild-type and amyloidogenic variants of lysozyme. These variants were used for comparative NMR and QCM studies to elucidate the structure, on a residual level, of a partially unfolded intermediate state important for the initial events of amyloid formation and to correlate these structural features with protein aggregation.



2) We applied complimentary biophysical techniques to gain str</gtr:description><gtr:exploitationPathways>This study has generated a greater understanding of the distinctive differences between species involved in normal and aberrant folding behaviour and we hope that it can contribute to the identification of novel strategies through which rational therapeutic intervention could lead to prevention or treatment, not just of lysozyme amyloidosis, but also perhaps the entire family of protein misfolding disorders.</gtr:exploitationPathways><gtr:id>4A59C73F-0999-4C8F-BA90-995547004677</gtr:id><gtr:sectors><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C705FA65-133E-40AC-9973-5D8ECA14AA8C"><gtr:id>C705FA65-133E-40AC-9973-5D8ECA14AA8C</gtr:id><gtr:title>Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bf5edbd3f4fbad35c3ab1d019e9abc44"><gtr:id>bf5edbd3f4fbad35c3ab1d019e9abc44</gtr:id><gtr:otherNames>Kumita JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/918B70F2-4B4B-4CCA-82FC-84D6D016AEDE"><gtr:id>918B70F2-4B4B-4CCA-82FC-84D6D016AEDE</gtr:id><gtr:title>Direct observation of the interconversion of normal and toxic forms of a-synuclein.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/85ce1c4f89fb58daed7d5111bbbf791e"><gtr:id>85ce1c4f89fb58daed7d5111bbbf791e</gtr:id><gtr:otherNames>Cremades N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6F9A973C-2129-4381-8CCB-4CA335C31934"><gtr:id>6F9A973C-2129-4381-8CCB-4CA335C31934</gtr:id><gtr:title>The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bf5edbd3f4fbad35c3ab1d019e9abc44"><gtr:id>bf5edbd3f4fbad35c3ab1d019e9abc44</gtr:id><gtr:otherNames>Kumita JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/024A5ECD-AE8F-440E-BAD3-5F3476CD2191"><gtr:id>024A5ECD-AE8F-440E-BAD3-5F3476CD2191</gtr:id><gtr:title>alpha2-Macroglobulin and haptoglobin suppress amyloid formation by interacting with prefibrillar protein species.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c54847da8a67aa82c170abcfb27ce794"><gtr:id>c54847da8a67aa82c170abcfb27ce794</gtr:id><gtr:otherNames>Yerbury JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BA5B0CBD-E1AC-4573-A2A5-162D175F411D"><gtr:id>BA5B0CBD-E1AC-4573-A2A5-162D175F411D</gtr:id><gtr:title>Hsp70 oligomerization is mediated by an interaction between the interdomain linker and the substrate-binding domain.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/87a55893e1bc92b7a6172ad6053e527d"><gtr:id>87a55893e1bc92b7a6172ad6053e527d</gtr:id><gtr:otherNames>Aprile FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1422C933-3F1A-42AF-B40E-B0A17BBA4683"><gtr:id>1422C933-3F1A-42AF-B40E-B0A17BBA4683</gtr:id><gtr:title>Methods and models in neurodegenerative and systemic protein aggregation diseases.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Landmark edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0c3f8b913c0f1c26cb10f35a40d4a9be"><gtr:id>0c3f8b913c0f1c26cb10f35a40d4a9be</gtr:id><gtr:otherNames>Brorsson AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1093-4715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE446244-5122-48D9-B4D6-9C7DCA26EE82"><gtr:id>BE446244-5122-48D9-B4D6-9C7DCA26EE82</gtr:id><gtr:title>The Significance of the Location of Mutations for the Native-State Dynamics of Human Lysozyme.</gtr:title><gtr:parentPublicationTitle>Biophysical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2105c1a1745a72be3266ff945b002f7f"><gtr:id>2105c1a1745a72be3266ff945b002f7f</gtr:id><gtr:otherNames>Ahn M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-3495</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/83DF58F7-76A2-4846-813E-245CB92441CA"><gtr:id>83DF58F7-76A2-4846-813E-245CB92441CA</gtr:id><gtr:title>Population of nonnative states of lysozyme variants drives amyloid fibril formation.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/41e28ad45f63b11e57e4bed174a7ddcb"><gtr:id>41e28ad45f63b11e57e4bed174a7ddcb</gtr:id><gtr:otherNames>Buell AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/368E62CC-2839-4CC8-9BE4-C863D1B5A011"><gtr:id>368E62CC-2839-4CC8-9BE4-C863D1B5A011</gtr:id><gtr:title>Protein amyloids develop an intrinsic fluorescence signature during aggregation.</gtr:title><gtr:parentPublicationTitle>The Analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00ddf4fbc16ad82ee40ebfdac6e70518"><gtr:id>00ddf4fbc16ad82ee40ebfdac6e70518</gtr:id><gtr:otherNames>Chan FT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-2654</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1C5CEFB-FC26-4620-A190-4E2FB1153789"><gtr:id>D1C5CEFB-FC26-4620-A190-4E2FB1153789</gtr:id><gtr:title>Structural characterization of toxic oligomers that are kinetically trapped during a-synuclein fibril formation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/57638f19b8724d9d700f65c0a31ff018"><gtr:id>57638f19b8724d9d700f65c0a31ff018</gtr:id><gtr:otherNames>Chen SW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D82AEEA0-E720-449E-B60B-58ED1C1DDB97"><gtr:id>D82AEEA0-E720-449E-B60B-58ED1C1DDB97</gtr:id><gtr:title>The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c54847da8a67aa82c170abcfb27ce794"><gtr:id>c54847da8a67aa82c170abcfb27ce794</gtr:id><gtr:otherNames>Yerbury JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0A9A5A5-05BE-4F81-B679-AD487EE9969A"><gtr:id>B0A9A5A5-05BE-4F81-B679-AD487EE9969A</gtr:id><gtr:title>Analysis of the native structure, stability and aggregation of biotinylated human lysozyme.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2105c1a1745a72be3266ff945b002f7f"><gtr:id>2105c1a1745a72be3266ff945b002f7f</gtr:id><gtr:otherNames>Ahn M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A7F1014-65B3-484E-9553-07E4C16D1F5D"><gtr:id>8A7F1014-65B3-484E-9553-07E4C16D1F5D</gtr:id><gtr:title>Structure of a low-population intermediate state in the release of an enzyme product.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a7cde2e3c0a64d25fecee81ccb974600"><gtr:id>a7cde2e3c0a64d25fecee81ccb974600</gtr:id><gtr:otherNames>De Simone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/063D937F-2FDF-416E-8DB9-C14D7C5F2C0D"><gtr:id>063D937F-2FDF-416E-8DB9-C14D7C5F2C0D</gtr:id><gtr:title>The non-core regions of human lysozyme amyloid fibrils influence cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36611388bfad1126b08d65b86961e512"><gtr:id>36611388bfad1126b08d65b86961e512</gtr:id><gtr:otherNames>Mossuto MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2CB0342A-F50F-4EDB-9027-D74C0D01F078"><gtr:id>2CB0342A-F50F-4EDB-9027-D74C0D01F078</gtr:id><gtr:title>Local cooperativity in an amyloidogenic state of human lysozyme observed at atomic resolution.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1f4b579ece82efcdde70786df140f297"><gtr:id>1f4b579ece82efcdde70786df140f297</gtr:id><gtr:otherNames>Dhulesia A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4D1C70FF-7597-4C8C-9A5B-7B40D588B7AC"><gtr:id>4D1C70FF-7597-4C8C-9A5B-7B40D588B7AC</gtr:id><gtr:title>Disulfide bonds reduce the toxicity of the amyloid fibrils formed by an extracellular protein.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/36611388bfad1126b08d65b86961e512"><gtr:id>36611388bfad1126b08d65b86961e512</gtr:id><gtr:otherNames>Mossuto MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34C486A1-BC81-406C-90A9-6E3A32C8202C"><gtr:id>34C486A1-BC81-406C-90A9-6E3A32C8202C</gtr:id><gtr:title>Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d37d1244eecbc020fa5a4645b0e2c503"><gtr:id>d37d1244eecbc020fa5a4645b0e2c503</gtr:id><gtr:otherNames>Chan PH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E7CC80C-3F76-46E6-B080-17AD56B8C2FA"><gtr:id>7E7CC80C-3F76-46E6-B080-17AD56B8C2FA</gtr:id><gtr:title>A non-natural variant of human lysozyme (I59T) mimics the in vitro behaviour of the I56T variant that is responsible for a form of familial amyloidosis.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42717d615f1c1093b44430f7327b33e0"><gtr:id>42717d615f1c1093b44430f7327b33e0</gtr:id><gtr:otherNames>Hagan CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6C1CA8E-5A4E-4B6F-A612-A5DA20901166"><gtr:id>C6C1CA8E-5A4E-4B6F-A612-A5DA20901166</gtr:id><gtr:title>Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40159b599b7312badb7cd9e61aafee60"><gtr:id>40159b599b7312badb7cd9e61aafee60</gtr:id><gtr:otherNames>Wyatt AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2200D7F1-753D-4B08-B681-20B7BF725B35"><gtr:id>2200D7F1-753D-4B08-B681-20B7BF725B35</gtr:id><gtr:title>A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc2f68bc8aa0742b91a863d7bb77b96c"><gtr:id>bc2f68bc8aa0742b91a863d7bb77b96c</gtr:id><gtr:otherNames>De Genst E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8606855A-9BDB-4D30-B4A1-B78E05EF188D"><gtr:id>8606855A-9BDB-4D30-B4A1-B78E05EF188D</gtr:id><gtr:title>Native-state stability determines the extent of degradation relative to secretion of protein variants from Pichia pastoris.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bef740745e66c0a6770f10110dd19a1a"><gtr:id>bef740745e66c0a6770f10110dd19a1a</gtr:id><gtr:otherNames>Whyteside G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E019927/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>